FTC Accuses Boehringer Of Subpoena Delay Tactics
The Federal Trade Commission, investigating a patent settlement between Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. that may have unlawfully delayed generic drug entry, has asked for a court order...To view the full article, register now.
Already a subscriber? Click here to view full article